[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Steven Paul Biography and Net Worth

Director of Alnylam Pharmaceuticals

Steven Paul has had a distinguished career in neuroscience, particularly in CNS drug discovery and development. Dr. Paul is the former President of the Lilly Research Laboratories of Eli Lilly and Company. Prior to his appointment at Weill Cornell, Dr. Paul spent 17-years at Eli Lilly, during which time he held several key leadership roles, including Vice President of Neuroscience (CNS) Research and Group Vice President of Discovery Research (all therapeutic areas). In his most recent role, he was responsible for the company's overall research and development efforts - helping to expand Lilly's R&D efforts in oncology and biotechnology - resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Dr. Paul served as Scientific Director of the National Institute of Mental Health.

Dr. Paul has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored over 500 papers and book chapters. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. He is also currently on the board of directors or is a trustee of several organizations, including the Sigma-Aldrich Corporation, Alnylam Pharmaceuticals, the Allen Institute for Brain Sciences, The Mind Research Network and the Foundation for the NIH. Dr. Paul has also served as a member of the National Institute of General Medical Sciences (NIGMS) Advisory Council and was appointed by the Secretary of the Department of Health and Human Services (HHS) as a member of the advisory committee to the Director of the NIH from 2001-2006. Dr. Paul is currently a member of the National Advisory Mental Health Council, NIMH, and is board certified by the American Board of Psychiatry and Neurology.

Dr. Paul received his B.A. in Biology and Psychology from Tulane University, and his M.S. and M.D. degrees from the Tulane University School of Medicine.

What is Steven M. Paul's net worth?: The estimated net worth of Steven M. Paul is at least $248,790.00 as of April 1st, 2022. Mr. Paul owns 1,000 shares of Alnylam Pharmaceuticals stock worth more than $248,790 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Paul may own. Learn More about Steven M. Paul's net worth.
How do I contact Steven M. Paul?: The corporate mailing address for Mr. Paul and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Steven M. Paul's contact information.
Has Steven M. Paul been buying or selling shares of Alnylam Pharmaceuticals?: Steven M. Paul has not been actively trading shares of Alnylam Pharmaceuticals in the last ninety days. Most recently, Steven M. Paul sold 15,000 shares of the business's stock in a transaction on Friday, April 1st. The shares were sold at an average price of $170.69, for a transaction totalling $2,560,350.00. Following the completion of the sale, the director now directly owns 1,000 shares of the company's stock, valued at $170,690. Learn More on Steven M. Paul's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 154,848 shares worth more than $34,733,444.48. The most recent insider tranaction occured on August, 20th when CEO Yvonne Greenstreet sold 15,000 shares worth more than $4,200,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 8/20/2024.

Steven M. Paul Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2022	Sell	15,000	$170.69	$2,560,350.00	1,000
12/18/2020	Sell	15,000	$140.00	$2,100,000.00	16,000
2/10/2020	Sell	30,000	$130.00	$3,900,000.00	31,000
1/26/2015	Buy	1,000	$95.00	$95,000.00

Steven M. Paul Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $248.79

$234.43

$249.10

50 Day Range

MA: $273.83

$232.27

$300.55

2 Week Range

Now: $248.79

$141.98

$304.39

Volume

1,058,682 shs

Average Volume

952,344 shs

Market Capitalization

$32.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39